NCT04260802 2026-01-12
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Ocellaris Pharma, Inc.
Phase 1/2 Terminated
Ocellaris Pharma, Inc.
G1 Therapeutics, Inc.
Case Comprehensive Cancer Center
Kyowa Kirin Co., Ltd.